DOUGLAS E. WILLIAMS - 19 Jan 2023 Form 4 Insider Report for Codiak BioSciences, Inc.

Role
President and Chief Executive Officer, Director
Signature
/s/ Yalonda Howze, Attorney-in-Fact for Douglas E. Williams
Issuer symbol
N/A
Transactions as of
19 Jan 2023
Net transactions value
-$2,918
Form type
4
Filing time
23 Jan 2023, 15:35:41 UTC
Previous filing
21 Feb 2023
Next filing
26 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CDAKQ Common Stock Options Exercise +13,667 +143% 23,252 19 Jan 2023 Direct F1
transaction CDAKQ Common Stock Sale $2,918 -5,075 -22% $0.5750* 18,177 20 Jan 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDAKQ Restricted Stock Units Options Exercise $0 -13,667 -33% $0.000000 27,333 19 Jan 2023 Common Stock 13,667 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2 The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement.
F3 Each RSU represents a contingent right to receive one share of common stock.
F4 On January 19, 2022, the reporting person was granted 41,000 RSUs, vesting in three equal annual installments beginning on the first anniversary of the grant date.

Remarks:

President and Chief Executive Officer